Effect of weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with heavily pretreated ovarian cancer

被引：0
|
作者：
Ikeda, Yuji
Kikuchi, Yoshihiro
Takano, Masashi
Goto, Tomoko
Kouta, Hiroko
Sasaki, Naoki
Kudoh, Kazuya
Oda, Katsutoshi
Nagasaka, Tsuneki
Kita, Tsunekazu
机构：
[1] Ohki Mem Canc Ctr Women, Tokorozawa, Saitama, Japan
[2] Natl Def Med Coll, Tokorozawa, Saitama 359, Japan
[3] Nishisaitama Chuo Natl Hosp, Tokorozawa, Saitama, Japan
[4] Univ Tokyo, Fac Med, Dept Obstet & Gynecol, Tokyo 113, Japan
[5] Kawakita Gen Hosp, Dept Obstet & Gynecol, Tokyo, Japan
[6] Nara Prefectural Nara Hosp, Nara, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5037
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
    GianMaria Miolo
    Ettore Bidoli
    Davide Lombardi
    Davide Adriano Santeufemia
    Giampiero Capobianco
    Francesco Dessole
    Simona Scalone
    Simon Spazzapan
    Roberto Sorio
    Gianna Tabaro
    Andrea Veronesi
    [J]. Archives of Gynecology and Obstetrics, 2012, 285 : 499 - 503
  • [32] Platelet-sparing effect of paclitaxel in heavily pretreated ovarian cancer patients
    Ishikawa H.
    Fujiwara K.
    Suzuki S.
    Tanaka Y.
    Kohno I.
    [J]. International Journal of Clinical Oncology, 2002, 7 (5) : 330 - 333
  • [33] Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer
    Soulie, P
    Bensmaine, A
    Garrino, C
    Chollet, P
    Brain, E
    Fereres, M
    Jasmin, C
    Musset, M
    Misset, JL
    Cvitkovic, E
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (09) : 1400 - 1406
  • [34] Effects of weekly bevacizumab and paclitaxel/carboplatin with or without sorafenib on heavily pretreated patients with recurrent or persistent cervical cancer.
    Kikuchi, Y.
    Takano, M.
    Goto, T.
    Kouta, H.
    Kikuchi, R.
    Kudoh, K.
    Kita, T.
    Furuya, K.
    Umayahara, K.
    Takizawa, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] BI-WEEKLY OXALIPLATIN (OXA) AND GEMCITABINE (GEM) IN CISPLATIN PRETREATED PATIENTS WITH RELAPSED OVARIAN CANCER (ROC): PRELIMINARY DATA FROM A PHASE II TRIAL
    Germano, D.
    Bilancia, D.
    Dello Russo, A.
    Dinota, A.
    Romano, R.
    Rosati, G.
    Manzione, L.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 94 - 94
  • [36] Bi-weekly oxaliplatin (oxa) and gemcitabine (gem) in cisplatin pretreated patients with relapsed ovarian cancer (roc): Preliminary data of a phase II trial.
    Germano, D
    Bilancia, D
    Di Nota, A
    Dello Russo, AM
    Romano, R
    Rosati, G
    Giotta, F
    Manzione, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 475S - 475S
  • [37] BEVACIZUMAB PLUS METRONOMIC CYCLOPHOSPHAMIDE FOR HEAVILY PRETREATED OVARIAN CANCER: A SINGLE INSTITUTION EXPERIENCE
    Ghanem, I.
    Mendiola, C.
    Diaz, A.
    Velasco, G.
    Manso, L.
    Ciruelos, E.
    Manneh, R. A.
    Hoyos, S.
    Pascual, T.
    Cortes-Funes, H.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 325 - 325
  • [38] Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer
    Watanabe, Yoh
    Koike, Eiji
    Nakai, Hidekatsu
    Etoh, Tomomaro
    Hoshiai, Hiroshi
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2008, 13 (04) : 345 - 348
  • [39] Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer
    Yoh Watanabe
    Eiji Koike
    Hidekatsu Nakai
    Tomomaro Etoh
    Hiroshi Hoshiai
    [J]. International Journal of Clinical Oncology, 2008, 13 : 345 - 348
  • [40] Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer
    Sanchez-Munoz, Alfonso
    Mendiola, Cesar
    Perez-Ruiz, Elisabeth
    Rodriguez-Sanchez, Cesar A.
    Miguel Jurado, Jose
    Alonso-Carrion, Lorenzo
    Ghanem, Ismael
    de Velasco, Guillermo
    Quero-Blanco, Cristina
    Alba, Emilio
    [J]. ONCOLOGY, 2010, 79 (1-2) : 98 - 104
12345